Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ
Real-time Data
01:30 PM
Day's Range
826.6452 wk Range
541.00Overview - REGN - Regeneron Pharmaceuticals, Inc.
Key Statistics
Valuation
Enterprise Value
77.99B
P/E (Trailing)
‪20.45‬
P/E (Forward)
‪13.76‬
PEG Ratio
‪-4.36‬
Price / Sales (TTM)
‪5.52‬
Price / Book
‪2.63‬
EV / EBITDA
‪16.58‬
Profitability
Gross Margin
‪86.56%‬
Profit Margin
‪27.86%‬
Operating Margin
‪33.10%‬
Return on Assets
‪6.52%‬
Return on Equity
‪14.04%‬
Ownership
Shares Outstanding
103.13M
Float
95.77M
Short % of Shares Outstanding
‪3.48%‬
Held by Insiders
‪2.08%‬
Held by Institutions
‪93.45%‬
Price stats
Beta
‪0.18‬
50-Day Avg
‪696.27‬
200-Day Avg
‪724.45‬
Dividends
Payout Ratio
‪9.01%‬
Frequency
Quarterly
Analyst Consensus
27 analysts
Average price target
‪$ 833.65‬Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - REGN - Regeneron Pharmaceuticals, Inc.
Peers - REGN - Regeneron Pharmaceuticals, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- REGNNASDAQRegeneron Pharmaceuticals, Inc.85.86BMarket Cap+31.37%52-week change20.45P/E (Trailing)‪27.86%‬Profit Margin
- ARGXNASDAQargenx SE American Depositary Receipt65.04BMarket Cap+34.86%52-week change39.69P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals Inc31.60BMarket Cap-87.81%52-week change41.15P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE29.28BMarket Cap+9.87%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.61BMarket Cap+23.98%52-week change19.38P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma, Inc.15.93BMarket Cap+41.98%52-week change-21.56P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBiomarin Pharmaceutical Inc.12.91BMarket Cap+12.29%52-week change180.27P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - REGN - Regeneron Pharmaceuticals, Inc.
About
Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases across eye care, immunology, oncology, cardiovascular health, and inflammation. Its current portfolio includes treatments such as Eylea and Eylea HD for retinal and eye…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
